CD44+/MyD88+卵巢癌转移、化疗耐药及预后的研究进展

卵巢癌是妇科三大恶性肿瘤之一,其死亡率居妇科恶性肿瘤首位，利用卵巢癌细胞表面标志分子的特异性，使化疗药物选择性地与卵巢癌细胞结合，可有效地消除肿瘤复发和抑制肿瘤耐药。寻找卵巢癌转移相关分子标记物并对其进行靶向治疗已成为研究热点，目前研究发现MyD88与CD44在卵巢癌中均有表达，并且在卵巢癌的发生发展和侵袭转移、耐药过程中起重要作用,本文着重对CD44+/MyD88+卵巢癌细胞的转移、化疗耐药及预后的研究进展进行综述。

Research Progress in Metastasis,Drug Resistance and Prognosis of CD44 +/MyD88 + Ovarian Cancer

Ovarian cancer is one of the three major malignant tumors of gynaecology oncology,and the motality of which comes first among gynecologic malignant tumors.Chemotherapy drugs selectively combined with ovarian cancer cells based on specificity of molecules marker on the surface of cancer cells can effectively eliminate the recurrence and drug resistance of cancer.Targeted therapy has become a focus of studying.Researches show that MyD88 and CD44 are expressed in ovarian cancer and play an important role in the development,invasion,metastasis,and drug-resistance of ovarian cancer.The major emphasis of this article is to review the latest researches on the metastasis,drug-resistance and prognosis related with the CD44 +/MyD88 + ovarian cancer.